0000950170-24-105995.txt : 20240912 0000950170-24-105995.hdr.sgml : 20240912 20240912170003 ACCESSION NUMBER: 0000950170-24-105995 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240910 FILED AS OF DATE: 20240912 DATE AS OF CHANGE: 20240912 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haas Jason CENTRAL INDEX KEY: 0001883821 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 241295579 MAIL ADDRESS: STREET 1: C/O SYROS PHARMACEUTICALS, INC. STREET 2: 35 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 ownership.xml 4 X0508 4 2024-09-10 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001883821 Haas Jason C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 false true false false Chief Financial Officer false Common Stock 2024-09-10 4 P false 35363 1.5493 A 59915 D Common Stock 2024-09-11 4 P false 19293 1.5781 A 79208 D Common Stock 2024-09-12 4 P false 45344 1.6762 A 124552 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. /s/ Todd Rosenthal, as attorney-in-fact 2024-09-12